{
    "clinical_study": {
        "@rank": "94306", 
        "arm_group": {
            "arm_group_label": "Pyrazoloacridine", 
            "arm_group_type": "Experimental", 
            "description": "Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of chemotherapy with pyrazoloacridine in\n      treating patients with stage IIIB or stage IV non-small cell lung cancer."
        }, 
        "brief_title": "Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Evaluate the antitumor activity of pyrazoloacridine (PZA) administered by\n      3-hour infusion to patients with advanced non small cell lung cancer (NSCLC). II. Determine\n      the qualitative and quantitative toxicities of PZA administered on this schedule. III.\n      Determine the response and survival durations of NSCLC patients treated with PZA.\n\n      OUTLINE: Single-Agent Chemotherapy. Pyrazoloacridine, PZA, NSC-366140.\n\n      PROJECTED ACCRUAL: If 2 or 3 responses are observed in the first 18 evaluable patients, 12\n      additional patients will be entered. Accrual is expected to take 5-12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed non small cell lung cancer ineligible\n        for higher priority protocols Sputum cytology acceptable Stage IIIB/IV Must have\n        measurable or evaluable disease Lesion outside prior radiotherapy fields Cytology-positive\n        pleural effusion and ascites are neither measurable nor evaluable No brain metastases on\n        CT\n\n        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: At\n        least 12 weeks Hematopoietic: Absolute granulocyte count greater than 2,000/mm3 Platelet\n        count greater than 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal: Creatinine\n        less than 1.5 mg/dL Other: No pregnant or nursing women Negative pregnancy test required\n        of fertile women Effective contraception required of fertile patients Blood/body fluid\n        analyses within 7 days prior to registration Imaging/exams for tumor measurement within 28\n        days prior to registration\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: One prior adjuvant\n        or neoadjuvant chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: At\n        least 4 weeks since radiotherapy and recovered AND Progressive disease outside of\n        radiation port Surgery: Recovered from any prior surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002656", 
            "org_study_id": "CDR0000064199", 
            "secondary_id": [
                "P30CA022453", 
                "WSU-C-1087-93", 
                "NCI-T94-0001H"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Pyrazoloacridine", 
            "description": "Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.\nDepending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level   +1 (820mg/m2); Level    0 (750mg/m2); Level   -1 (600mg/m2)", 
            "intervention_name": "pyrazoloacridine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "NSC 366140"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "recurrent non-small cell lung cancer", 
            "stage IIIB non-small cell lung cancer", 
            "stage IV non-small cell lung cancer"
        ], 
        "lastchanged_date": "April 25, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/WSU-C-1087-93"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Detroit", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48201"
                }, 
                "name": "Barbara Ann Karmanos Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA", 
        "overall_official": {
            "affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "last_name": "Antoinette J. Wozniak, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2001", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluate toxicity of pyrazoloacridine.", 
            "safety_issue": "Yes", 
            "time_frame": "Weekly prior to each treatment cycle."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002656"
        }, 
        "secondary_outcome": {
            "measure": "Evaluate the response frequency of pyrazoloacridine.", 
            "safety_issue": "No", 
            "time_frame": "After 2 treatment cycles then every 2 months"
        }, 
        "source": "Barbara Ann Karmanos Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Barbara Ann Karmanos Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 1995", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Barbara Ann Karmanos Cancer Institute": "42.331 -83.046"
    }
}